[Bushen Daozhuo Granules for type Ⅲ prostatitis: A multicenter randomized controlled clinical trial].
Da-Lin Sun,Bin Cai,Bao-Fang Jin,Guo-Shou Xia,Zhi-An Tang,Wen-Tao Yang,Qiang Zou,Guo-Hong Song,Jian-Guo Liu,Hong-le Zhao,Ning Dai,Jia-Hui Wang,Ya-Long Gu,Ya-Lin Zhai
DOI: https://doi.org/10.13263/j.cnki.nja.2017.02.012
2017-01-01
Abstract:OBJECTIVE:To study the safety and efficacy of Bushen Daozhuo Granules (BDG) in the treatment of type Ⅲ prostatitis.
METHODS:This multicenter randomized controlled clinical trial included 478 patients with type Ⅲ prostatitis, 290 in the trial group and 188 as controls, the former treated with BDG at 200 ml bid and the latter with tamsulosin hydrochloride sustainedrelease capsules at 0.2 mg qd, both for 4 weeks. Before treatment, after 4 weeks of medication, and at 4 weeks after drug withdrawal, we obtained the NIH Chronic Prostatitis Symptom Index (NIHCPSI) scores and compared the safety and effectiveness rate between the two groups of patients.
RESULTS:Compared with the baseline, the NIHCPSI score was markedly decreased in the control group after 4 weeks of medication (21.42 ± 4.02 vs 15.67 ± 3.65, P < 0.05) but showed no statistically significant difference from that at 4 weeks after drug withdrawal (19.03 ± 3.86) (P>0.05), while the NIHCPSI score in the trial group was remarkably lower than the baseline both after 4 weeks of medication and at 4 weeks after drug withdrawal (10.92 ± 2.06 and 12.91 ± 2.64 vs 21.58 ± 3.67, P < 0.05). The trial group exhibited both a higher rate of total effectiveness and safety than the control (P < 0.05).
CONCLUSIONS:BDG is safe and effective for the treatment of type Ⅲ prostatitis.